Table 1 Baseline characteristics of anti-HER2, anti-HER2 combined immunotherapy and external hospital cohorts
Characteristic | Anti-HER2 cohort (n = 271) | Anti-HER2 combined immunotherapy cohort (n = 119) | External cohort (n = 39) |
|---|---|---|---|
Age | |||
Median, IQR | 63, 55–69 | 65, 58–72 | 60, 55–68 |
Sex | |||
Male | 225 (83.03%) | 95 (79.83%) | 30 (76.92%) |
Female | 46 (16.97%) | 24 (20.17%) | 9 (23.08%) |
Tumor site | |||
GEJ | 82 (30.26%) | 35 (29.41%) | 8 (20.51%) |
Non-GEJ | 189 (69.74%) | 84 (70.59%) | 31 (79.49%) |
Degree of differentiation | |||
Poorly | 132 (48.71%) | 62 (52.10%) | 23 (58.97%) |
Moderately | 129 (47.60%) | 56 (47.06%) | 14 (35.90%) |
Well | 10 (3.69%) | 1 (0.84%) | 2 (5.13%) |
Lauren type | |||
Intestinal | 17 (63.84%) | 82 (68.91%) | 6 (15.79%) |
Diffused | 34 (12.55%) | 12 (10.08%) | 1 (2.63%) |
Mixed | 43 (15.87%) | 16 (13.45%) | 1 (2.63%) |
N/A | 21 (7.75%) | 9 (7.56%) | 31 (79.49%) |
PD-L1 expression | |||
Positive | 44 (16.24%) | 43 (36.13%) | 8 (20.51%) |
Negative | 60 (22.14%) | 25 (21.01%) | 8 (20.51%) |
N/A | 167 (61.62%) | 51 (42.86%) | 23 (58.97%) |
MMR status | |||
pMMR | 137 (50.55%) | 104 (87.39%) | 18 (46.15%) |
dMMR | 2 (0.74%) | 1 (0.84%) | 0 (0.00%) |
N/A | 132 (48.71%) | 14 (11.76%) | 21 (53.85%) |
EBV status | |||
Positive | 3 (1.11%) | 1 (0.84%) | 0 (0.00%) |
Negative | 119 (43.91%) | 89 (74.79%) | 9 (23.08%) |
N/A | 149 (54.98%) | 29 (24.37%) | 30 (76.92%) |
TNM stages | |||
III | 4 (1.48%) | 3 (2.52%) | 1 (2.56%) |
IV | 267 (98.52%) | 116 (97.48%) | 38 (97.44%) |
